We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-3 of 3

FTC’s proposed rules would generate more HSR filings for transfers of pharmaceutical patent rights

  • McDermott Will & Emery
  • -
  • USA
  • -
  • August 16 2012

The U.S. Federal Trade Commission’s new proposed Hart-Scott-Rodino Act rules will apply only to transfers of pharmaceutical patent rights and are expected to increase the number of filings

2nd Circuit urges en banc rehearing on pay-for-delay

  • McDermott Will & Emery
  • -
  • USA
  • -
  • June 30 2010

The U.S. Court of Appeals for the Second Circuit found that reverse payment settlements of patent infringement lawsuits that keep generic drug manufacturers out of the marketplace do not violate federal antitrust laws

Final FTC rules will generate more HSR filings for transfers of pharmaceutical patent rights

  • McDermott Will & Emery
  • -
  • USA
  • -
  • November 7 2013

The U.S. Federal Trade Commission (FTC) announced final changes to the Hart-Scott-Rodino (HSR) Act premerger notification rules that will broaden the